Syndax to present entinostat data against cancer at AACR meeting

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

More... (http://www.news-medical.net/news/20110401/Syndax-to-present-entinostat-data-against-cancer-at-AACR-meeting.aspx)